Skip to main content

 Documents to download can be found at the bottom of the page.

 Dear members of the EHNS,

We are planning to conduct a randomized non-inferiority trial comparing a standard and a de-escalated follow-up schedule for the endpoint 5-year overall survival post-randomization after complete clinical response after surgery and/or radio(chemo)therapy. If you are interested in the possibility of collaboration, you can find the slides presented at the EORTC head and neck group meeting from March 2019, the trial proposal form from the Swiss Group for Clinical Cancer Research (SAKK) and a budget scenario which is subject to change. Based on the funding we receive, we are planning to offer patient fees (to the participating center) ranging from CHF 2000 – 2500 per randomized patient.

The preliminary assessments of SAKK board and EORTC Head and Neck working groups were positive. However, we definitely need international collaboration due to the sample size (n = 800 patients) and the need to complete the trial in a given period. Therefore, we were asked to run a survey to evaluate the potential interest and capacity to join.

We would be glad, if you could consider the possibility of a collaboration, that you fill out the short excel table attached and return to us until 31.05.2019.

Looking forward to your answers (negative feedbacks also appreciated).

Many thanks and kind regards,

Olgun Elicin, M.D.
Department of Radiation Oncology
Inselspital, Bern University Hospital
3010 Bern, Switzerland
(This email address is being protected from spambots. You need JavaScript enabled to view it.)

PD Dr. med. Roland Giger
Vice-Director, Chief physician
Department of ENT, Head and Neck Surgery
Inselspital, Bern University Hospital
3010 Bern, Switzerland
(This email address is being protected from spambots. You need JavaScript enabled to view it.)

Documents

  1. HNSCC Follow-Up - EORTC 13.03.2019
  2. SAKK Trial Proposal Form V2.1
  3. Survey for EHNS members
  4. Trial_budget_draft_example

 

 

  • Hits: 3013